Pure Biologics Stock

Pure Biologics ROCE

The Return on Capital Employed (ROCE) of Pure Biologics (PUR.WA) as of Aug 6, 2026 is 94.41 %. In the previous year, Return on Capital Employed (ROCE) was -1,676.23 % — a change of -105.63% (higher).

ROCE

94.41 %

YoY

-105.63%

Last updated:

In 2026, Pure Biologics's return on capital employed (ROCE) was 94.41 %, a -105.63% increase from the -1,676.23 % ROCE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Pure Biologics's Return on Capital Employed (ROCE)

Pure Biologics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Pure Biologics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Pure Biologics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Pure Biologics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Pure Biologics stock

Return on Capital Employed (ROCE) of Pure Biologics is 94.41 % in 2026.

Return on Capital Employed (ROCE) of Pure Biologics changed from -1,676.23 % to 94.41 %, representing a -105.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Pure Biologics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Pure Biologics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Pure Biologics